TIMM13 (Translocase of Inner Mitochondrial Membrane Subunit 13), also known as TIM13 or Mitochondrial Import Protein 13, is a small chaperone protein located in the mitochondrial intermembrane space (IMS) that plays a critical role in the import of nuclear-encoded proteins into mitochondria [1]. This gene encodes a 104-amino acid protein that functions as part of the small TIM chaperone complex, specifically the TIM8/13 complex, which facilitates the import of hydrophobic inner membrane proteins [2].
Mitochondrial dysfunction is a central pathological feature of major neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), and Huntington's disease (HD). The TIMM13-mediated protein import pathway is essential for maintaining mitochondrial function, and alterations in this pathway contribute to neurodegeneration [3].
| Attribute | Value |
|---|---|
| Gene Symbol | TIMM13 |
| Full Name | Translocase of Inner Mitochondrial Membrane Subunit 13 |
| Previous Symbols | TIM13, MIPL |
| Chromosomal Location | 19p13.3 |
| NCBI Gene ID | 10430 |
| OMIM | 607497 |
| Ensembl ID | ENSG00000120437 |
| UniProt ID | Q9Y2H5 |
| Protein Length | 104 amino acids |
| Molecular Weight | ~10.5 kDa |
| Gene Family | Small TIM family |
The TIMM13 gene consists of 4 coding exons spanning approximately 5 kb of genomic DNA. The gene is located on the minus strand of chromosome 19 at position 19p13.3. The promoter region contains binding sites for transcription factors involved in mitochondrial biogenesis, including NRF-1 (Nuclear Respiratory Factor 1) and NRF-2.
TIMM13 is a small, cysteine-rich protein with distinctive structural features [4]:
TMRE Domain Structure:
┌─────────────────────────────────────────┐
│ IMS (Intermembrane Space) │
├─────────────────────────────────────────┤
│ Cys-rich domain (Zn-binding) │
│ [CX5C-X10-CX5C-X4C] │
├─────────────────────────────────────────┤
│ Inner Mitochondrial Membrane │
└─────────────────────────────────────────┘
Key Structural Features:
The three-dimensional structure reveals a β-grasp fold typical of small IMS proteins, with the zinc-binding domain critical for chaperone function.
TIMM13 undergoes several post-translational modifications:
TIMM13 functions within the mitochondrial protein import machinery [5]:
Cytosol → TOM Complex → IMS → TIM22 Complex → Inner Membrane
↓
TIM8/13 Complex
(chaperone activity)
Import Process:
TIMM13 is a core component of the small TIM chaperone system in mitochondria [6]:
| Complex | Components | Function |
|---|---|---|
| TIM8/13 | TIMM8A + TIMM13 | Import of carrier proteins (e.g., ADP/ATP carrier) |
| TIM9/10 | TIMM9 + TIMM10 + TIMM10B | Import of metabolite carriers |
| TIM8/9/10 | TIMM8A + TIMM9 + TIMM10 | Import of multi-pass inner membrane proteins |
The TIM8/13 complex specifically facilitates import of:
TIMM13 recognizes substrate proteins based on:
TIMM13 expression varies across tissues:
| Tissue | Expression Level | Significance |
|---|---|---|
| Brain | High | Neuronal energy requirements |
| Heart | Very High | Continuous energy demand |
| Skeletal Muscle | High | Contractile function |
| Liver | Moderate | Metabolic function |
| Kidney | Moderate | Transport functions |
| Pancreas | Moderate | Insulin secretion |
Within the brain, TIMM13 is highly expressed in:
Mitochondrial dysfunction is a hallmark of AD pathology, and TIMM13 contributes through several mechanisms [3:1]:
Pathogenesis:
Evidence:
Molecular Mechanisms:
Aβ Accumulation
↓
TOM/TIM Import Dysfunction
↓
TIMM13 Function Impairment
↓
Respiratory Chain Deficit
↓
ATP Depletion + ROS
↓
Synaptic Dysfunction + Neuronal Death
PD features prominent mitochondrial dysfunction, with TIMM13 playing a role [7]:
Pathogenesis:
Evidence:
The PINK1/Parkin mitophagy pathway interacts with TIMM13 function [8]:
Amyotrophic Lateral Sclerosis (ALS):
Huntington's Disease (HD):
Aging:
Strategies to enhance mitochondrial function via TIMM13 [9]:
| Approach | Mechanism | Status |
|---|---|---|
| PGC-1α Activators | Upregulate mitochondrial biogenesis genes | Preclinical |
| AMPK Activators | Enhance energy metabolism | Clinical trials |
| SIRT1 Activators | Deacetylate mitochondrial proteins | Research |
| TFAM Expression | Increase mitochondrial DNA transcription | Experimental |
Key Targets:
Combating oxidative stress in mitochondrial diseases [10]:
| Compound | Target | Development Stage |
|---|---|---|
| Coenzyme Q10 | Electron transport chain | Approved (some indications) |
| MitoQ | Mitochondria-specific antioxidant | Clinical trials |
| Idebenone | Complex I activity | Clinical trials |
| Vitamin E | Lipid peroxidation | Research |
Direct targeting of the import machinery:
Several models have been developed:
Knockout Studies:
Transgenic Models:
Zebrafish provide accessible models:
TIMM13 as a biomarker:
Key questions remain: